15 assets in Acute Myeloid Leukemia, MLL Gene Rearrangement

Therapeutic assets addressing Acute Myeloid Leukemia, MLL Gene Rearrangement, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cytarabine Acute Myeloid Leukemia, MLL Gene Rearrangement	National Cancer Institute (NCI)	P2	B (60)
Revumenib Acute Myeloid Leukemia, MLL Gene Rearrangement	National Cancer Institute (NCI)	P2	B (60)
Calaspargase Pegol Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Fludarabine Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Hydrocortisone Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Prednisolone Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Prednisone Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Vincristine Sulfate Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (53)
Methotrexate Acute Myeloid Leukemia, MLL Gene Rearrangement	Children's Oncology Group	P2	CCC (51)
Azacitidine Acute Myeloid Leukemia, MLL Gene Rearrangement	Kura Oncology, Inc.	P1	CC (43)
Daunomycin Acute Myeloid Leukemia, MLL Gene Rearrangement	National Cancer Institute (NCI)	P1	CC (43)
Gilteritinib Acute Myeloid Leukemia, MLL Gene Rearrangement	Uma Borate	P1	CC (43)
Quizartinib Acute Myeloid Leukemia, MLL Gene Rearrangement	Kura Oncology, Inc.	P1	CC (43)
Venetoclax Acute Myeloid Leukemia, MLL Gene Rearrangement	Kura Oncology, Inc.	P1	CC (43)
Ziftomenib Acute Myeloid Leukemia, MLL Gene Rearrangement	Kura Oncology, Inc.	P1	CC (43)